Table 1.
Overall (n = 486) | Q1: >0.79 mg/L (n = 122) | Q2: 0.79-1.60 mg/L (n = 122) | Q3: 1.61-3.78 mg/L (n = 122) | Q4: ≥3.79 mg/L (n = 120) | |
---|---|---|---|---|---|
Age, y | 51 ± 9 | 52 ± 9 | 51 ± 9 | 52 ± 9 | 51 ± 9 |
Female sex | 188 (39) | 70 (57) | 42 (34) | 43 (35) | 33 (28) |
Race | |||||
White | 368 (76) | 104 (85) | 93 (76) | 93 (76) | 78 (65) |
Black | 86 (18) | 10(8) | 23 (19) | 21 (17) | 32 (27) |
Other | 32 (7) | 8 (7) | 6 (5) | 8 (7) | 10(8) |
Treatment group | |||||
High-dose vitamin | 240 (49) | 56 (46) | 62 (51) | 61 (50) | 61 (51) |
Low-dose vitamin | 246 (51) | 66 (54) | 60 (49) | 61 (50) | 59 (49) |
Country | |||||
United States | 337 (69) | 96 (79) | 85 (70) | 89 (73) | 67 (56) |
Canada | 57 (12) | 15(12) | 19 (16) | 12 (10) | 11 (9) |
Brazil | 92 (19) | 11 (9) | 18 (15) | 18 (15) | 42 (35) |
Time since transplantation, y | 3.86 [1.70–7.05] | 4.64 [2.34–8.56] | 4.30 [1.68–7.79] | 3.77 [1.80–6.59] | 2.61 [1.04–5.85] |
Living donor kidney | 207 (43) | 44 (36) | 59 (48) | 55 (45) | 49 (41) |
Calcineurin inhibitor use | 427 (88) | 104 (85) | 114 (93) | 105 (86) | 104 (87) |
Sirolimus use | 49 (10) | 11 (9) | 4 (3) | 13(11) | 21 (18) |
CVD | 93 (19) | 16 (13) | 22 (18) | 29 (24) | 26 (22) |
Diabetes | 178 (37) | 44 (36) | 47 (39) | 50 (41) | 37 (31) |
Smoking status | |||||
Never | 242 (50) | 64 (53) | 68 (56) | 55 (45) | 55 (46) |
Current | 57 (12) | 11 (9) | 12 (10) | 10(8) | 24 (20) |
Ever | 187 (39) | 47 (39) | 42 (34) | 57 (47) | 41 (34) |
BMI, kg/m2 | 29.0 ± 5.9 | 28.6 ± 6.0 | 29.1 ± 6.1 | 29.6 ± 5.8 | 28.6 ± 5.9 |
SBP, mm Hg | 136 ± 20.0 | 131 ± 19 | 133 ± 17 | 136 ± 20 | 143 ± 22 |
DBP, mm Hg | 79 ± 13 | 76 ± 11 | 78 ± 10 | 79 ± 13 | 84 ± 14 |
eGFR, mL/min/1.73 m2 | 46 ± 18 | 49 ± 18 | 50 ± 19 | 46 ± 18 | 40 ± 15 |
Urine ACR, mg/g | 24.5 [9.5–105.6] | 10.7 [5.5–30.0] | 16.2 [6.9–45.6] | 41.0 [12.2–174.0] | 76.1 [19.9–257.2] |
Note: Values for categorical variables are given as count (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range]. Among the 491 person sub-cohort, 486 had urine available for alpha 1 microglobulin measurement.
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FAVORIT, Folic Acid for Vascular Outcome Reduction in Transplantation; Q, quartile; SBP, systolic blood pressure.